Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma

Melanoma Research

Volumn 16, Issue 4, 2006, Pages 357-363

  Masucci, Giuseppe Valentino ^a   Månsson Brahme, Eva ^a   Ragnarsson Olding, Boel ^a   Nilsson, Bo ^a   Wagenius, Gunnar ^b   Hansson, Johan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chemo immunotherapy; Interleukin 2; Melanoma; Temozolomide

Indexed keywords

RECOMBINANT INTERLEUKIN 2; SCH 52365; TEMOZOLOMIDE;

ADULT; AGED; ARTHRALGIA; ARTICLE; BRAIN METASTASIS; CANCER GROWTH; CANCER RELAPSE; CENTRAL NERVOUS SYSTEM METASTASIS; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EPIGASTRIC PAIN; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; INJECTION SITE INFLAMMATION; INSOMNIA; MALE; MELANOMA; MYALGIA; NAUSEA; OCULAR PRURITUS; OUTPATIENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SHIVERING; THROMBOCYTOPENIA; TUMOR GROWTH; VOMITING; WORLD HEALTH ORGANIZATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; FEMALE; HUMANS; IMMUNOTHERAPY; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; KIDNEY NEOPLASMS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 33746224205     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cmr.0000205019.23612.a1     Document Type: Article

References (38)

1. Oldham RK. Biological response modifiers program workshop 'In vivo effects of IL-2'. J Biol Response Modifiers 1984; 3:455-532.
2. Cheever MA, Greenberg PD, Fefer A, Gillis S. Augmentation of the antitumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2. J Exp Med 1982; 155:968-980.
3. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155:1823-1841.
4. Lafreniere R, Rosenberg SA. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. J Immunol 1985; 135:4273-4280.
5. Mazumder A, Rosenberg SA. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med 1984; 159:495-507.
6. Moertel CG. On lymphokines, cytokines, and breakthroughs. JAMA 1986; 256:3141.
7. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316:898-905.
8. de Gast GC, Batchelor D, Kersten MJ, Vyth-Dreese FA, Sein J, van de Kasteele WF, et al. Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma. Br J Cancer 2003; 88:175-180.
9. Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CA, et al. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 1985; 135:2865-2875.
10. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313:1485-1492.
11. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. JAMA 1986; 256:3117-3124.
12. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316:889-897.
13. Rosenberg SA. The development of new immunotherapies for the treatment of cancer using interleukin-2. A review. Ann Surg 1988; 208:121-135.
14. Rosenberg SA. Immunotherapy of cancer using interleukin 2: current status and future prospects. Immunol Today 1988; 9:58-62.
15. Thompson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Levitt D, et al. Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. J Clin Oncol 1988; 6:669-678.
16. Philip T, Mercatello A, Negrier S, Philip I, Rebattu P, Kaemmerlin P, et al. Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: the Lyon first-year experience in 20 patients. Cancer Treat Rev 1989; 16(Suppl A):91-104.
17. Stoter G, Shiloni E, Gundersen S, Cleton FJ, Iacobelli S, Bijman JT, et al. Alternating recombinant human interleukin-2 and dacarbazine in advanced melanoma. A multicentric phase II study. Cancer Treat Rev 1989; 16(Suppl A):59-63.
18. Kolitz JE, Wong GY, Weite K, Merluzzi VJ, Engert A, Bialas T, et al. Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2. J Biol Response Mod 1988; 7:457-472.
19. Atzpodien J, Korfer A, Evers P, Franks CR, Knuver-Hopf J, Lopez-Hanninen E, et al. Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study. Mol Biother 1990; 2:18-26.
20. Atkins MB, Gollob JA, Sosman JA, McDermott DF, Tutin L, Sorokin P, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Clin Cancer Res 2002; 8:3075-3081.
21. Buzaid AC, Legha SS. Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma. Semin Oncol 1994; 21(Suppl 14):23-28.
22. Masucci G, Svensson A, Hansson M, Hansson J, Nakazawa T, Salazar F, et al. Efficient harvest of in vivo IL-2-activated CD3+ lymphocytes for adoptive immunotherapy by selective leukapheresis (lymphocytapheresis). J Hematother 1997; 6:253-260.
23. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl- imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M&B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987; 47:5846-5852.
24. Stevens MF, Newlands ES. From triazines and triazenes to temozolomide. Eur J Cancer 1993; 29A:1045-1047.
25. Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992; 65:287-291.
26. Dhodapkar M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC, et al. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 1997; 3:1093-1100.
27. Brada M, Judson I, Beale P, Moore S, Reidenberg P, Statkevich P, et al. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 1999; 81:1022-1030.
28. Baker SD, Wirth M, Statkevich P, Reidenberg P, Alton K, Sartorius SE, et al. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 1999; 5:309-317.
29. Patel M, McCully C, Godwin K, Balis FM. Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol 2003; 61:203-207.
30. Bleehen NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, et al. Cancer research campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995; 13:910-913.
31. Berd D, Mastrangelo MJ. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide. Cancer Invest 1988; 6:337-349.
32. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158-166.
33. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999; 17:2762-2771.
34. Kaufmann R, Spieth K, Leiter U, Mauch C, von den Driesch P, Vogt T, et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the dermatologic cooperative oncology group. J Clin Oncol 2005; 23:9001-9007.
35. Saris SC, Patronas NJ, Rosenberg SA, Alexander JT, Frank J, Schwartzentruber DJ, et al. The effect of intravenous interleukin-2 on brain water content. J Neurosurg 1989; 71:169-174.
36. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 Study. Lancet 2000; 356:1384-1391.
37. Bergh J. Where next with stem-cell-supported high-dose therapy for breast cancer? Lancet 2000; 355:944-945.
38. Paul MJ, Summers Y, Calvert AH, Rustin G, Brampton MH, Thatcher N, et al. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res 2002; 12:175-178.